Neurodevelopmental Disorders in the PICU Population

Sarah A Sobotka1, Sarah Peters1, Neethi P Pinto1

  • 11 University of Chicago, Chicago, IL, USA.

Clinical Pediatrics
|November 4, 2017
PubMed

Insights

Children in the pediatric intensive care unit (PICU) have a high rate of undiagnosed neurodevelopmental disorders, including attention deficit hyperactivity disorder (ADHD). Early identification and support are crucial for this vulnerable population.

Area of Science:

  • Pediatric critical care medicine
  • Neurodevelopmental disorders
  • Child psychology

Background:

  • Attention deficit hyperactivity disorder (ADHD) affects 11% of children and adolescents, increasing risks for injury and illness.
  • The prevalence of ADHD and other developmental disorders in pediatric intensive care units (PICUs) remains understudied.
  • Children with neurodevelopmental disorders may be more susceptible to the impacts of critical illness.

Purpose of the Study:

  • To investigate the prevalence of ADHD and other neurodevelopmental disorders in children admitted to a PICU.
  • To understand the baseline neurodevelopmental status of critically ill children.
  • To inform future support strategies for this population.

Main Methods:

  • A single-center, prospective cohort study was conducted.
  • Children aged 6 to 12 years hospitalized in the PICU were enrolled.
  • Parental interviews regarding neurodevelopmental history and validated ADHD/behavioral disorder screening tools were used.

Main Results:

  • Twenty-four children were enrolled in the study.
  • Ten patients (42%) had a pre-existing neurodevelopmental diagnosis.
  • Seven patients (29%) met the study criteria for ADHD at enrollment.

Conclusions:

  • Critically ill children in the PICU exhibit a high prevalence of neurodevelopmental disabilities.
  • These children are at increased risk for adverse developmental and behavioral outcomes following critical illness.
  • Further research is essential to develop targeted interventions for this vulnerable group.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
338
Disorders of the Nervous Tissue01:28

Disorders of the Nervous Tissue

Nervous tissue is a vital component of the human body's communication system, enabling us to perceive and respond to stimuli. However, like all other tissues, it is vulnerable to disorders and diseases that can significantly impact our neurological functioning.
Homeostatic Imbalances:
Alzheimer's disease manifests as a gradual decline in memory and cognitive abilities, attributed to the buildup of amyloid plaques and neurofibrillary tangles in the brain.
Parkinson's disease arises from the...
2.7K
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
289
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
258